The week in pharma: action, reaction and insight – week to November 4, 2022
By Barbara Obstoj-Cardwell. Editor
Featured research news last week included US pharma major Bristol Myers Squibb releasing top-line results from a Phase III study suggesting its Reblozyl can address a wider myelodysplastic syndrome patient group. Actinium Pharmaceuticals reported positive top-line Phase III results for it acute myeloid leukemia (AML) candidate Iomab-B. Also, US pharma giant Pfizer last Tuesday presented strong data for its RSVpreF respiratory syncytial virus (RSV) vaccine program. On the deal-making front, US MRNA technology company Arcturus Therapeutics hit the jackpot last week, inking a potentially hugely lucrative deal with Australian biotech CSL Limited, to access the firm’s late-stage self-amplifying mRNA (sa-mRNA) vaccine platform technology.
Positive COMMANDS data for Reblozyl in first-line MDS
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze